ImmuneOnco Biopharmaceuticals (Shanghai) Inc. completed an on-market repurchase of 25,400 H shares on 3 July 2026, paying between HKD 3.80 and HKD 3.93 per share. The transaction totalled HKD 0.10 million, based on a volume-weighted consideration of HKD 98,196.

Following the buyback, ImmuneOnco’s outstanding H-share count slipped by 0.0061 % to 419.01 million, while treasury shares rose to 1.47 million. The company’s aggregate issued share capital remains at 420.48 million shares, unchanged as the repurchased stock is being held in treasury rather than cancelled.

The purchase was executed under the repurchase mandate approved on 28 May 2026, which authorises the company to buy back up to 43.15 million shares. To date, 1.47 million shares—equivalent to 0.34 % of the issued share base at mandate date—have been repurchased under this authority.

In line with Hong Kong Listing Rules, ImmuneOnco is subject to a moratorium on issuing new shares or selling treasury stock until 3 August 2026.